Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 268 clinical trials
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Primary Objective: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients (2 to <18 years old). Secondary Objective: Evaluate the efficacy of eliglustat and quality of life in pediatric patients (2 to <18 years old).

bone disease
gaucher disease
alglucerase
imiglucerase
cerezyme
  • 0 views
  • 19 Feb, 2024
  • 19 locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

tamoxifen
HER2
endocrine therapy
anastrozole
oestrogen receptor positive breast cancer
  • 0 views
  • 19 Feb, 2024
  • 126 locations
SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer

Primary Objective: To determine whether SAR439859 in combination with palbociclib improves progression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: To compare the overall survival …

solid tumour
her2/neu-negative breast cancer
HER2
breast cancer
palbociclib
  • 0 views
  • 19 Feb, 2024
  • 5 locations
A Communication Enhancing Intervention to Improve Patients' Perception of Physiotherapy Consultations

The aim of this study is to test the effectiveness of a single training session in communication skills at improving patients' perceptions of physiotherapy consultations.

physiotherapy
  • 0 views
  • 19 Feb, 2024
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.The study consists of 3 periods:Screening period: 2 to 4 weeks.Treatment period: 24 weeks.Post-intervention follow-up period: 16 weeks.

  • 0 views
  • 14 May, 2025
Unannounced Meal Handling of Advanced Closed Loop Insulin Delivery in Monitored Condition

The study will follow participants for the periods of 3 months while using an advanced hybrid closed loop algorithm in free living conditions . Each period will have a different meal handling protocols.

insulin
type 1 diabetes mellitus
  • 0 views
  • 19 Feb, 2024
A Pilot Study of High Intensity Walking in Older Adults in the Pre-operative Period

The purpose of this pilot study is to evaluate a high intensity walking intervention in older surgical candidates with kidney or thoracic disease and pre-frailty or frailty.

  • 0 views
  • 19 Feb, 2024
A Study to Evaluate the Pharmacokinetics Safety and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

Secondary objectives include evaluating the effect of mitapivat on electrocardiogram (ECG) parameters, including concentration-QT interval corrected for heart rate (C-QTc) analysis under fasted conditions. The study will include a 28-day screening period, four 7-day treatment periods. Participants will receive a follow-up telephone call within 28 (1) days after the last …

cervical cap
12 lead electrocardiogram
electrocardiogram
12 lead ECG
drug test
  • 0 views
  • 19 Feb, 2024
SubsTRate OxidatioN in Girls

In addition, subjective appetite will be measured throughout the assessment periods.

  • 0 views
  • 19 Feb, 2024
A Multinational Randomized Double-blind Placebo-controlled Study to Assess the Efficacy Pharmacodynamics Pharmacokinetics and Safety of Venglustat in Late-onset GM2

Primary Objectives: Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period Secondary population (participants with juvenile/adolescent late-onset GM2 gangliosidosis, GM1 gangliosidosis, saposin C deficiency, sialidosis type 1 or juvenile/adult galactosialidosis): To assess …

  • 0 views
  • 19 Feb, 2024
  • 2 locations